Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL28858713 | 0.86 | BCHE (0.39) | BCHEMAPTBUB1NFKB1NFKB2 | |
| SCHEMBL26985563 | 0.75 | BCHE (0.38) | BCHEUSP2SMN1; SMN2MAPTBUB1 | |
| SCHEMBL320438 | 0.75 | P2RX4 (0.48) | BCHEMAPTALDH1A1BLMGMNN | |
| SCHEMBL3630207 | 0.75 | P2RX4 (0.48) | BCHEMAPTALDH1A1BLMGMNN | |
| SCHEMBL9162472 | 0.74 | BCHE (0.43) | BCHEUSP2SMN1; SMN2CTSKMAPT | |
| SCHEMBL3748240 | 0.74 | BCHE (0.43) | BCHEUSP2SMN1; SMN2CTSKMAPT | |
| SCHEMBL18919395 | 0.74 | BCHE (0.41) | BCHEUSP2SMN1; SMN2MAPTBUB1 | |
| SCHEMBL10447847 | 0.72 | BCHE (0.42) | BCHEUSP2SMN1; SMN2MAPTKDM4E | |
| SCHEMBL5121655 | 0.72 | BCHE (0.54) | BCHEBUB1DTYMKALDH1A1GPR119 | |
| SCHEMBL1678307 | 0.71 | GSK3A (0.57) | BCHESMN1; SMN2MAPTALDH1A1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0492254-B1 | Process for the preparation of N-(tert-butoxycarbonyl)maleimide | SIEMENS AG (DE) | 1999-03-17 | — | — | EP | claimed |
| US-5691110-A | DISSOLVING POLYMER IN SOLVENT; HEATING | LUCENT TECHNOLOGIES INC. (US) | 1997-11-25 | — | — | US | claimed |
| EP-0608983-B1 | A process for controlled deprotection of polymers and a process for fabricating a device utilizing partially deprotected resist polymers | AT & T CORP (US) | 1997-11-12 | — | — | EP | claimed |
| US-5385809-A | Partially deprotecting a polymer having a pendant and labile alkoxycarbonyl or alkyl groups prior to use as a photoresist; lithography | AT&T CORP. (US) | 1995-01-31 | — | — | US | claimed |
| EP-0608983-A1 | A process for controlled deprotection of polymers and a process for fabricating a device utilizing partially deprotected resist polymers | AT&T Corp. (US) | 1994-08-03 | — | — | EP | claimed |
| US-5247096-A | Reaction of maleimide and di-tert-butyl carbonate in the presence of base | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | claimed |
| EP-0523556-A1 | Process for the production of N-tert.-butoxycarbonyl-maleimide | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-01-20 | — | — | EP | claimed |
| EP-0492254-A1 | N-(tert-Butoxycarbonyl)maleimide | SIEMENS AKTIENGESELLSCHAFT (DE) | 1992-07-01 | — | — | EP | claimed |
| US-5019488-A | Method of producing an image reversal negative photoresist having a photo-labile blocked imide | HOECHST CELANESE CORPORATION (US) | 1991-05-28 | — | — | US | claimed |
| US-4775609-A | Image reversal | HOESCHT CELANESE CORPORATION (US) | 1988-10-04 | — | — | US | claimed |
| JP-5262729-A | — | — | None | — | — | JP | disclosed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-115066422-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-4912018-A | High resolution photoresist based on imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1990-03-27 | — | — | US | disclosed |
| US-4837124-A | High resolution photoresist of imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0292821-A2 | Image reversal process for normally positive photoresists | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-30 | — | — | EP | disclosed |
| US-4775609-A | Image reversal | HOESCHT CELANESE CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0234327-A2 | High resolution photoresist of imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | BCHE 490/4885USP2 314/4885SMN1; SMN2 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.